Symbols / ACRS
ACRS Chart
About
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 364.04M |
| Enterprise Value | 270.37M | Income | -141.68M | Sales | 15.74M |
| Book/sh | 1.11 | Cash/sh | 0.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | 61 | IPO | — |
| P/E | — | Forward P/E | -6.11 | PEG | — |
| P/S | 23.13 | P/B | 3.03 | P/C | — |
| EV/EBITDA | -4.11 | EV/Sales | 17.18 | Quick Ratio | 3.92 |
| Current Ratio | 3.92 | Debt/Eq | 1.87 | LT Debt/Eq | — |
| EPS (ttm) | -1.58 | EPS next Y | -0.55 | EPS Growth | — |
| Revenue Growth | -24.10% | Earnings | 2026-02-26 | ROA | -22.98% |
| ROE | -113.23% | ROIC | — | Gross Margin | -275.68% |
| Oper. Margin | -5.17% | Profit Margin | 0.00% | Shs Outstand | 108.35M |
| Shs Float | 82.01M | Short Float | 5.49% | Short Ratio | 1.70 |
| Short Interest | — | 52W High | 4.89 | 52W Low | 1.05 |
| Beta | 0.86 | Avg Volume | 1.82M | Volume | 1.55M |
| Target Price | $8.00 | Recom | Strong_buy | Prev Close | $3.25 |
| Price | $3.36 | Change | 3.38% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$3.36
Latest analyst target
3. DCF / Fair value
$-9.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.36
Low
$2.00
High
$16.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2026-01-21 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-05-28 | init | Wedbush | — → Outperform | $8 |
| 2025-05-14 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-05-09 | main | Scotiabank | Sector Outperform → Sector Outperform | $9 |
| 2025-03-18 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $15 |
| 2024-12-23 | up | HC Wainwright & Co. | Neutral → Buy | $20 |
| 2024-11-19 | up | Leerink Partners | Market Perform → Outperform | $7 |
| 2024-11-19 | up | Jefferies | Hold → Buy | $7 |
| 2024-11-19 | up | BTIG | Neutral → Buy | $8 |
| 2024-11-18 | up | Piper Sandler | Neutral → Overweight | $13 |
| 2024-09-17 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-19 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-07-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-01-22 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-01-11 | down | BTIG | Buy → Neutral | — |
| 2023-12-29 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
- Aclaris tests experimental asthma antibody in new human trial - Stock Titan ue, 24 Feb 2026 12
- There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump - simplywall.st ue, 03 Feb 2026 08
- What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now? - Yahoo Finance ue, 21 Oct 2025 07
- Can Aclaris Therapeutics Stock Hold Up When Markets Turn? - Trefis Sun, 21 Dec 2025 08
- HC Wainwright & Co. Reiterates Aclaris Therapeutics (ACRS) Buy Recommendation - Nasdaq Mon, 20 Oct 2025 07
- Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - Sahm Mon, 26 Jan 2026 08
- Cantor Fitzgerald maintains Overweight on Aclaris stock, cites multi-bagger potential - Investing.com Wed, 15 Oct 2025 07
- Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - GlobeNewswire Fri, 19 Dec 2025 08
- Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Investing News Network hu, 06 Nov 2025 08
- Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight - Yahoo Finance Sun, 21 Sep 2025 07
- New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan ue, 06 Jan 2026 08
- Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? - Nasdaq Wed, 30 Jul 2025 07
- Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? - Yahoo Finance Sun, 12 Oct 2025 07
- Experimental atopic dermatitis drug begins new safety trial in patients - Stock Titan Mon, 12 Jan 2026 08
- Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans? - simplywall.st hu, 04 Sep 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 63475 | — | — | WALKER NEAL | Chief Executive Officer | — | 2026-02-03 00:00:00 | D | nan |
| 1 | 20875 | — | — | LOEROP JAMES | Officer | — | 2026-02-03 00:00:00 | D | nan |
| 2 | 22025 | — | — | BALTHASER KEVIN J | Chief Financial Officer | — | 2026-02-03 00:00:00 | D | nan |
| 3 | 18675 | — | — | DAVIS HUGH M. | President | — | 2026-02-03 00:00:00 | D | nan |
| 4 | 33500 | — | — | LOEROP JAMES | Officer | — | 2026-01-30 00:00:00 | D | nan |
| 5 | 14750 | — | — | BALTHASER KEVIN J | Chief Financial Officer | — | 2026-01-30 00:00:00 | D | nan |
| 6 | 29150 | — | — | WALKER NEAL | Chief Executive Officer | — | 2026-01-02 00:00:00 | D | nan |
| 7 | 91900 | — | — | LOEROP JAMES | Officer | — | 2026-01-02 00:00:00 | D | nan |
| 8 | 94450 | — | — | BALTHASER KEVIN J | Chief Financial Officer | — | 2026-01-02 00:00:00 | D | nan |
| 9 | 26750 | — | — | DAVIS HUGH M. | President | — | 2025-12-02 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 78.30K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 37.69M | -134.41M | -79.66M | -40.12M |
| TotalUnusualItems | -89.41M | 18.96M | -4.70M | -24.34M |
| TotalUnusualItemsExcludingGoodwill | -89.41M | 18.96M | -4.70M | -24.34M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -132.06M | -88.48M | -86.91M | -90.86M |
| ReconciledDepreciation | 807.00K | 863.00K | 797.00K | 923.00K |
| ReconciledCostOfRevenue | 15.46M | 18.08M | 11.96M | 4.71M |
| EBITDA | -51.72M | -115.45M | -84.36M | -64.46M |
| EBIT | -52.53M | -116.31M | -85.15M | -65.38M |
| NormalizedIncome | -42.66M | -107.36M | -82.21M | -66.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -132.06M | -88.48M | -86.91M | -90.86M |
| TotalExpenses | 71.25M | 147.56M | 114.91M | 72.14M |
| TotalOperatingIncomeAsReported | -141.93M | -97.36M | -89.85M | -89.72M |
| DilutedAverageShares | 77.30M | 69.81M | 65.21M | 56.73M |
| BasicAverageShares | 77.30M | 69.81M | 65.21M | 56.73M |
| DilutedEPS | -1.71 | -1.27 | -1.33 | -1.60 |
| BasicEPS | -1.71 | -1.27 | -1.33 | -1.60 |
| DilutedNIAvailtoComStockholders | -132.06M | -88.48M | -86.91M | -90.86M |
| NetIncomeCommonStockholders | -132.06M | -88.48M | -86.91M | -90.86M |
| NetIncome | -132.06M | -88.48M | -86.91M | -90.86M |
| NetIncomeIncludingNoncontrollingInterests | -132.06M | -88.48M | -86.91M | -90.86M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | ||
| NetIncomeContinuousOperations | -132.06M | -88.48M | -86.91M | -90.86M |
| TaxProvision | 0.00 | -367.00K | 0.00 | 0.00 |
| PretaxIncome | -132.06M | -88.85M | -86.91M | -90.86M |
| OtherIncomeExpense | -79.54M | 27.47M | -1.75M | -25.48M |
| OtherNonOperatingIncomeExpenses | 9.87M | 8.51M | 2.95M | -1.14M |
| SpecialIncomeCharges | -89.41M | 18.96M | -4.70M | -24.34M |
| WriteOff | 0.00 | 1.31M | 0.00 | |
| ImpairmentOfCapitalAssets | 6.63M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 89.41M | -20.27M | 4.70M | 24.34M |
| OperatingIncome | -52.53M | -116.31M | -85.15M | -65.38M |
| OperatingExpense | 55.79M | 129.48M | 102.95M | 67.43M |
| ResearchAndDevelopment | 33.59M | 98.38M | 77.81M | 43.81M |
| SellingGeneralAndAdministration | 22.20M | 31.10M | 25.13M | 23.62M |
| GeneralAndAdministrativeExpense | 22.20M | 31.10M | 25.13M | 23.62M |
| OtherGandA | 8.63M | 10.80M | 8.96M | 23.62M |
| SalariesAndWages | 13.57M | 20.30M | 16.17M | 14.10M |
| GrossProfit | 3.26M | 13.17M | 17.79M | 2.05M |
| CostOfRevenue | 15.46M | 18.08M | 11.96M | 4.71M |
| TotalRevenue | 18.72M | 31.25M | 29.75M | 6.76M |
| OperatingRevenue | 18.72M | 31.25M | 29.50M | 6.64M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 107.85M | 70.89M | 66.69M | 61.23M |
| ShareIssued | 107.85M | 70.89M | 66.69M | 61.23M |
| TotalDebt | 426.00K | 684.00K | 693.00K | |
| TangibleBookValue | 155.55M | 157.18M | 190.65M | 190.29M |
| InvestedCapital | 155.55M | 157.18M | 197.62M | 197.34M |
| WorkingCapital | 94.36M | 97.90M | 209.61M | 182.10M |
| NetTangibleAssets | 155.55M | 157.18M | 190.65M | 190.29M |
| CapitalLeaseObligations | 426.00K | 684.00K | 693.00K | |
| CommonStockEquity | 155.55M | 157.18M | 197.62M | 197.34M |
| TotalCapitalization | 155.55M | 157.18M | 197.62M | 197.34M |
| TotalEquityGrossMinorityInterest | 155.55M | 157.18M | 197.62M | 197.34M |
| StockholdersEquity | 155.55M | 157.18M | 197.62M | 197.34M |
| GainsLossesNotAffectingRetainedEarnings | 97.00K | -106.00K | -897.00K | -224.00K |
| OtherEquityAdjustments | 97.00K | -106.00K | -897.00K | -224.00K |
| RetainedEarnings | -902.86M | -770.80M | -682.32M | -595.41M |
| AdditionalPaidInCapital | 1.06B | 928.08M | 880.83M | 792.97M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 1.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 64.77M | 40.23M | 56.98M | 53.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 33.18M | 9.27M | 35.04M | 30.94M |
| OtherNonCurrentLiabilities | 13.14M | 9.27M | 34.67M | 30.57M |
| NonCurrentDeferredLiabilities | 20.04M | 0.00 | 367.00K | 367.00K |
| NonCurrentDeferredRevenue | 20.04M | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 0.00 | 367.00K | 367.00K | |
| CurrentLiabilities | 31.60M | 30.95M | 21.94M | 22.93M |
| OtherCurrentLiabilities | 2.68M | 2.63M | 2.20M | 2.20M |
| CurrentDeferredLiabilities | 7.82M | 0.00 | ||
| CurrentDeferredRevenue | 3.89M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 426.00K | 684.00K | 693.00K | |
| CurrentCapitalLeaseObligation | 426.00K | 684.00K | 693.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.98M | 3.91M | 5.29M | 4.39M |
| PayablesAndAccruedExpenses | 16.12M | 24.41M | 13.76M | 15.65M |
| CurrentAccruedExpenses | 11.43M | 15.54M | 3.41M | 5.66M |
| Payables | 4.69M | 8.88M | 10.35M | 9.98M |
| AccountsPayable | 4.69M | 8.88M | 10.35M | 9.98M |
| TotalAssets | 220.33M | 197.41M | 254.60M | 251.21M |
| TotalNonCurrentAssets | 94.38M | 68.55M | 23.05M | 46.18M |
| OtherNonCurrentAssets | 3.07M | 4.16M | 2.73M | 3.55M |
| InvestmentsAndAdvances | 90.30M | 62.77M | 12.24M | 34.24M |
| OtherInvestments | 34.24M | |||
| InvestmentinFinancialAssets | 90.30M | 62.77M | 12.24M | 34.24M |
| AvailableForSaleSecurities | 90.30M | 62.77M | 12.24M | 34.24M |
| GoodwillAndOtherIntangibleAssets | 269.00K | 6.97M | 7.05M | |
| OtherIntangibleAssets | 269.00K | 6.97M | 7.05M | |
| NetPPE | 1.01M | 1.62M | 1.10M | 1.33M |
| AccumulatedDepreciation | -4.80M | -4.16M | -4.04M | -3.39M |
| GrossPPE | 5.81M | 5.78M | 5.13M | 4.73M |
| Leases | 817.00K | 817.00K | 1.12M | 1.12M |
| OtherProperties | 3.14M | 3.15M | 2.01M | 1.60M |
| MachineryFurnitureEquipment | 1.86M | 1.81M | 2.00M | 2.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 125.95M | 128.86M | 231.55M | 205.03M |
| OtherCurrentAssets | 12.04M | 9.45M | 13.49M | 12.99M |
| PrepaidAssets | 12.99M | |||
| Receivables | 318.00K | 298.00K | 484.00K | 623.00K |
| AccountsReceivable | 318.00K | 298.00K | 484.00K | 623.00K |
| CashCashEquivalentsAndShortTermInvestments | 113.59M | 119.11M | 217.57M | 191.41M |
| OtherShortTermInvestments | 89.02M | 79.23M | 172.29M | 164.06M |
| CashAndCashEquivalents | 24.57M | 39.88M | 45.28M | 27.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -56.01M | -79.63M | -68.17M | -52.44M |
| RepaymentOfDebt | 0.00 | 0.00 | -11.48M | |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 74.91M | 26.71M | 72.74M | 238.20M |
| CapitalExpenditure | -35.93M | -1.31M | -605.00K | -308.00K |
| EndCashPosition | 24.57M | 39.88M | 45.28M | 27.35M |
| BeginningCashPosition | 39.88M | 45.28M | 27.35M | 22.06M |
| ChangesInCash | -15.31M | -5.40M | 17.93M | 5.29M |
| FinancingCashFlow | 74.54M | 26.71M | 72.87M | 225.05M |
| CashFlowFromContinuingFinancingActivities | 74.54M | 26.71M | 72.87M | 225.05M |
| NetOtherFinancingCharges | -409.00K | -102.00K | -34.00K | -3.12M |
| ProceedsFromStockOptionExercised | 32.00K | 94.00K | 157.00K | 1.46M |
| NetCommonStockIssuance | 74.91M | 26.71M | 72.74M | 238.20M |
| CommonStockIssuance | 74.91M | 26.71M | 72.74M | 238.20M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -11.48M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -11.48M | |
| LongTermDebtPayments | 0.00 | 0.00 | -11.48M | |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -69.77M | 46.22M | 12.63M | -167.63M |
| CashFlowFromContinuingInvestingActivities | -69.77M | 46.22M | 12.63M | -167.63M |
| NetInvestmentPurchaseAndSale | -33.84M | 47.53M | 13.23M | -167.32M |
| SaleOfInvestment | 86.14M | 183.20M | 177.99M | 67.83M |
| PurchaseOfInvestment | -119.98M | -135.68M | -164.75M | -235.15M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -35.81M | 0.00 | ||
| PurchaseOfIntangibles | -35.81M | 0.00 | ||
| NetPPEPurchaseAndSale | -121.00K | -1.31M | -605.00K | -308.00K |
| PurchaseOfPPE | -121.00K | -1.31M | -605.00K | -308.00K |
| OperatingCashFlow | -20.07M | -78.33M | -67.57M | -52.13M |
| CashFlowFromContinuingOperatingActivities | -20.07M | -78.33M | -67.57M | -52.13M |
| ChangeInWorkingCapital | 10.92M | 9.39M | -1.20M | -1.34M |
| ChangeInOtherWorkingCapital | 23.93M | |||
| ChangeInPayablesAndAccruedExpense | -8.13M | 10.52M | 960.00K | 4.12M |
| ChangeInAccruedExpense | -3.94M | 11.99M | 592.00K | 470.00K |
| ChangeInPayable | -4.19M | -1.47M | 368.00K | 3.65M |
| ChangeInAccountPayable | -4.19M | -1.47M | 368.00K | 3.65M |
| ChangeInPrepaidAssets | -4.86M | -1.31M | -2.29M | -5.62M |
| ChangeInReceivables | -20.00K | 186.00K | 139.00K | 149.00K |
| ChangesInAccountReceivables | -20.00K | 186.00K | 139.00K | 149.00K |
| OtherNonCashItems | 89.41M | -20.27M | 4.70M | 24.34M |
| StockBasedCompensation | 10.86M | 20.54M | 15.04M | 14.06M |
| AssetImpairmentCharge | 6.63M | 0.00 | 0.00 | |
| DeferredTax | 0.00 | -367.00K | 0.00 | 0.00 |
| DeferredIncomeTax | 0.00 | -367.00K | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 807.00K | 863.00K | 797.00K | 923.00K |
| DepreciationAndAmortization | 807.00K | 863.00K | 797.00K | 923.00K |
| OperatingGainsLosses | 752.00K | |||
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -132.06M | -88.48M | -86.91M | -90.86M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACRS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|